Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02000167
Other study ID # 136271
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 2012
Est. completion date May 2015

Study information

Verified date June 2015
Source University of Arkansas
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to determine whether a relationship exists between gene deletion(s) specific to the mitochondrial electron transport chain and presentation of clinical characteristics in patients with Phelan-McDermid Syndrome (PMS).


Description:

Phelan-McDermid Syndrome (PMS) results from a deletion within the 22q13 chromosome region. Most children have specific physical morphology and developmental delays with many displaying characteristics of autism spectrum disorder (ASD) including abnormalities in social development. The behavioral aspect of PMS that parallels ASD has raised particular interest as the SHANK3 gene, which lies in the 22q13 region, is important for synaptic development, and animal SHANK3 knockout models demonstrate ASD characteristics thereby confirming the importance of this gene in PMS. However, despite the importance of the SHANK3 gene, individuals with PMS have variations in their development, behavior and medical characteristics that cannot be fully explained by the SHANK3 deletion. Recently, Frye (2012) has noted the existence of 6 mitochondrial genes that lie slightly proximal to the SHANK3 gene within the 22q13 region. These include genes important electron transport change function (SCO2, NDUFA6), mitochondrial DNA (TYMP) and RNA (TRMU) metabolism, fatty acid metabolism (CPT1B) and tricarboxylic acid cycle function (ACO2). Since most Individuals with PMS have deletions that include chromosomal deletion outside of the SHANK3 region, it is very likely that many, if not most, of children with PMS may have deletions in these mitochondrial genes. Many of these genes have been linked to mitochondrial disease, even in the heterozygous state. Even if recognized, mitochondrial disease is only linked to a homozygous abnormal state (autosomal recessive), the loss of one gene (heterozygous state) could result in symptomatology when associated with deletions in other mitochondrial or non-mitochondrial genes. Abnormalities in mitochondrial pathways can result in neurologic and non-neurologic symptoms including those sometimes seen in children with PMS. Added with the SHANK3 deletion, abnormalities in these mitochondrial genes could explain variations in patterns of development and the eventual cognitive potential. References: Frye RE. Mitochondrial disease in 22q13 duplication syndrome. J Child Neurol. 2012; 27(7):942-9.


Recruitment information / eligibility

Status Completed
Enrollment 51
Est. completion date May 2015
Est. primary completion date May 2015
Accepts healthy volunteers No
Gender All
Age group 1 Year to 21 Years
Eligibility Inclusion Criteria: - 1-21 years of age - Diagnosed with Phelan-McDermid Syndrome AND diagnosed with Mitochondrial Disorder - Diagnosed with Phelan-McDermid Syndrome Exclusion Criteria: - none

Study Design


Locations

Country Name City State
United States Arkansas Children's Hospital Research Institute Little Rock Arkansas

Sponsors (2)

Lead Sponsor Collaborator
University of Arkansas St. Christopher's Hospital for Children

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Electron Transport Chain function derived from buccal cells of known PMS patients Electron transport chain (ETC) function will be measured in cells collected using Buccal swabs to determine if certain PMS patients symptomatology and clinical characteristics/variations can be explained due to variations in patterns of ETC function in this cohort Up to two years
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT03493607 - AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy Phase 2
Completed NCT03426059 - Mapping the Phenotype in Adults With Phelan-McDermid Syndrome
Recruiting NCT02461420 - Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
Enrolling by invitation NCT04312152 - Q10 Ubiquinol in Autism Spectrum Disorder and in Phelan-McDermid Syndrome. N/A
Completed NCT05105685 - Effectiveness of Recombinant Human Growth Hormone Therapy for Children With PMS Phase 1/Phase 2
Enrolling by invitation NCT05187377 - A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism Phase 2
Completed NCT01525901 - Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome) Phase 2
Active, not recruiting NCT05025241 - An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001) Phase 2
Completed NCT02710084 - Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome Phase 2